SINGAPORE (Aug 26): iX Biopharma is a small Catalist-listed Singapore company focusing on a big goal: Developing pain management drugs that are an alternative to opioids, and the optimum system to deliver these drugs into the body.

One of its patents is WaferiX, a technology that reduces a drug to a wafer-thin tablet to be placed under the tongue for quick absorption, a sublingual drug delivery system that is believed to be the most effective after intravenous therapy.

iX Biopharma has also developed and produced Wafermine, a sublingual wafer of ketamine. Wafermine is already in use in some Australian hospitals after physicians discovered its efficacy on the Australian victims of the 2002 Bali bombings who were recreational drug users and had developed a resistance to opioids.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook